1. Home
  2. OCC vs KLRS Comparison

OCC vs KLRS Comparison

Compare OCC & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Optical Cable Corporation

OCC

Optical Cable Corporation

HOLD

Current Price

$5.57

Market Cap

48.8M

Sector

Industrials

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$10.49

Market Cap

46.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCC
KLRS
Founded
1983
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.8M
46.0M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
OCC
KLRS
Price
$5.57
$10.49
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$20.67
AVG Volume (30 Days)
93.5K
54.9K
Earning Date
03-20-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
290.91
N/A
EPS
N/A
N/A
Revenue
$87,828,590.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
37.03
N/A
52 Week Low
$2.40
$2.14
52 Week High
$11.50
$11.90

Technical Indicators

Market Signals
Indicator
OCC
KLRS
Relative Strength Index (RSI) 49.28 55.24
Support Level $4.19 $8.08
Resistance Level $5.98 $10.36
Average True Range (ATR) 0.72 1.11
MACD 0.02 0.10
Stochastic Oscillator 18.44 71.61

Price Performance

Historical Comparison
OCC
KLRS

About OCC Optical Cable Corporation

Optical Cable Corp manufactures tight-buffered fiber optic & copper data communication cables, data communication connectivity solutions for enterprise markets, and customized solutions for specialty use & harsh environments. Its products and services include designs and customized products for specialty applications and harsh environments, cabling, connectors, patch cords, assemblies, racks, cabinets, datacom enclosures, patch panels, faceplates, and multi-media boxes. The company supplies its products and services to industries such as the military, industrial, mining, petrochemical, renewable energy and broadcast applications, and for the wireless carrier market.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: